{
  "success": true,
  "pagesUsed": [
    3,
    4,
    5,
    7,
    14,
    15,
    19,
    20,
    21,
    22,
    23,
    25,
    26,
    29,
    47,
    48,
    49,
    55,
    58,
    59
  ],
  "modelUsed": "claude-opus-4-5",
  "confidence": 1.0,
  "scheduling": {
    "timings": [
      {
        "id": "timing_1",
        "name": "Screening Period Duration",
        "type": "Within",
        "unit": "weeks",
        "instanceType": "Timing",
        "value": 8,
        "relativeTo": "Baseline",
        "windowLower": -8,
        "windowUpper": 0
      },
      {
        "id": "timing_2",
        "name": "Extended Screening Period",
        "type": "Within",
        "unit": "weeks",
        "instanceType": "Timing",
        "value": 10,
        "relativeTo": "Baseline",
        "windowLower": -10,
        "windowUpper": 0
      },
      {
        "id": "timing_3",
        "name": "SARS-CoV-2 Extended Screening",
        "type": "Within",
        "unit": "weeks",
        "instanceType": "Timing",
        "value": 12,
        "relativeTo": "Baseline",
        "windowLower": -12,
        "windowUpper": 0
      },
      {
        "id": "timing_4",
        "name": "F4cc Extended Screening Period",
        "type": "Within",
        "unit": "weeks",
        "instanceType": "Timing",
        "value": 24,
        "relativeTo": "Baseline",
        "windowLower": -24,
        "windowUpper": 0
      },
      {
        "id": "timing_5",
        "name": "Screening Visit 1",
        "type": "At",
        "unit": "weeks",
        "instanceType": "Timing",
        "value": -8,
        "relativeTo": "Baseline",
        "windowLower": 0,
        "windowUpper": 0
      },
      {
        "id": "timing_6",
        "name": "Screening Visit 2",
        "type": "At",
        "unit": "weeks",
        "instanceType": "Timing",
        "value": -6,
        "relativeTo": "Baseline",
        "windowLower": 0,
        "windowUpper": 0
      },
      {
        "id": "timing_7",
        "name": "Day -4 Visit (Visit 4a2)",
        "type": "At",
        "unit": "days",
        "instanceType": "Timing",
        "value": -4,
        "relativeTo": "Baseline",
        "windowLower": 0,
        "windowUpper": 0
      },
      {
        "id": "timing_8",
        "name": "Abdominal MRI Window",
        "type": "Between",
        "unit": "days",
        "instanceType": "Timing",
        "value": -7,
        "relativeTo": "Baseline",
        "windowLower": -7,
        "windowUpper": -4
      },
      {
        "id": "timing_9",
        "name": "Treatment Period Duration",
        "type": "Within",
        "unit": "weeks",
        "instanceType": "Timing",
        "value": 24,
        "relativeTo": "First Dose",
        "windowLower": 0,
        "windowUpper": 24
      },
      {
        "id": "timing_10",
        "name": "Dosing Interval",
        "type": "At",
        "unit": "weeks",
        "instanceType": "Timing",
        "value": 4,
        "relativeTo": "Previous Visit",
        "windowLower": 0,
        "windowUpper": 0
      },
      {
        "id": "timing_11",
        "name": "Last Dose Administration",
        "type": "At",
        "unit": "weeks",
        "instanceType": "Timing",
        "value": 20,
        "relativeTo": "First Dose",
        "windowLower": 0,
        "windowUpper": 0
      },
      {
        "id": "timing_12",
        "name": "Safety Follow-up Period",
        "type": "Within",
        "unit": "weeks",
        "instanceType": "Timing",
        "value": 12,
        "relativeTo": "Last Dose",
        "windowLower": 0,
        "windowUpper": 12
      },
      {
        "id": "timing_13",
        "name": "Historical Liver Biopsy Window",
        "type": "Between",
        "unit": "weeks",
        "instanceType": "Timing",
        "value": 24,
        "relativeTo": "Screening",
        "windowLower": -24,
        "windowUpper": -4
      },
      {
        "id": "timing_14",
        "name": "Maximum Historical Biopsy to First Dose",
        "type": "Within",
        "unit": "weeks",
        "instanceType": "Timing",
        "value": 34,
        "relativeTo": "First Dose",
        "windowLower": -34,
        "windowUpper": 0
      },
      {
        "id": "timing_15",
        "name": "F4cc Historical Biopsy Window",
        "type": "Within",
        "unit": "weeks",
        "instanceType": "Timing",
        "value": 10,
        "relativeTo": "Screening",
        "windowLower": -10,
        "windowUpper": 0
      },
      {
        "id": "timing_16",
        "name": "First Screening After Historical Biopsy",
        "type": "After",
        "unit": "weeks",
        "instanceType": "Timing",
        "value": 4,
        "relativeTo": "Screening",
        "windowLower": 4
      },
      {
        "id": "timing_17",
        "name": "SV2 to Day -4 Minimum Interval",
        "type": "After",
        "unit": "weeks",
        "instanceType": "Timing",
        "value": 2,
        "relativeTo": "Previous Visit",
        "windowLower": 2
      },
      {
        "id": "timing_18",
        "name": "Live Vaccine Washout",
        "type": "Before",
        "unit": "days",
        "instanceType": "Timing",
        "value": 30,
        "relativeTo": "Baseline",
        "windowLower": 30
      },
      {
        "id": "timing_19",
        "name": "Leukocyte Apheresis Washout",
        "type": "Before",
        "unit": "days",
        "instanceType": "Timing",
        "value": 30,
        "relativeTo": "Baseline",
        "windowLower": 30
      },
      {
        "id": "timing_20",
        "name": "Anti-integrin/Adhesion Molecule Washout",
        "type": "Before",
        "unit": "days",
        "instanceType": "Timing",
        "value": 90,
        "relativeTo": "Baseline",
        "windowLower": 90
      },
      {
        "id": "timing_21",
        "name": "Immunomodulatory Biologic Washout",
        "type": "Before",
        "unit": "days",
        "instanceType": "Timing",
        "value": 90,
        "relativeTo": "Baseline",
        "windowLower": 90
      },
      {
        "id": "timing_22",
        "name": "Prior NASH Study Washout",
        "type": "Before",
        "unit": "months",
        "instanceType": "Timing",
        "value": 6,
        "relativeTo": "Baseline",
        "windowLower": 180
      },
      {
        "id": "timing_23",
        "name": "Vitamin E/TZD/GLP-1 RA Stable Dose",
        "type": "Before",
        "unit": "months",
        "instanceType": "Timing",
        "value": 3,
        "relativeTo": "Screening",
        "windowLower": 90
      },
      {
        "id": "timing_24",
        "name": "Methadone/Buprenorphine Stable Treatment",
        "type": "Before",
        "unit": "months",
        "instanceType": "Timing",
        "value": 6,
        "relativeTo": "Screening",
        "windowLower": 180
      },
      {
        "id": "timing_25",
        "name": "Hepatotoxic Medication Washout",
        "type": "Before",
        "unit": "weeks",
        "instanceType": "Timing",
        "value": 24,
        "relativeTo": "Screening",
        "windowLower": 168
      },
      {
        "id": "timing_26",
        "name": "Contraception Duration Post-Treatment",
        "type": "After",
        "unit": "weeks",
        "instanceType": "Timing",
        "value": 12,
        "relativeTo": "Last Dose",
        "windowLower": 0,
        "windowUpper": 12
      },
      {
        "id": "timing_27",
        "name": "Breastfeeding Restriction Post-Treatment",
        "type": "After",
        "unit": "weeks",
        "instanceType": "Timing",
        "value": 12,
        "relativeTo": "Last Dose",
        "windowLower": 0,
        "windowUpper": 12
      },
      {
        "id": "timing_28",
        "name": "Week 12 FibroScan Assessment",
        "type": "At",
        "unit": "weeks",
        "instanceType": "Timing",
        "value": 12,
        "relativeTo": "First Dose",
        "windowLower": 0,
        "windowUpper": 0
      },
      {
        "id": "timing_29",
        "name": "Week 24 Liver Biopsy",
        "type": "At",
        "unit": "weeks",
        "instanceType": "Timing",
        "value": 24,
        "relativeTo": "First Dose",
        "windowLower": 0,
        "windowUpper": 0
      },
      {
        "id": "timing_30",
        "name": "Week 36 End of Follow-up",
        "type": "At",
        "unit": "weeks",
        "instanceType": "Timing",
        "value": 36,
        "relativeTo": "First Dose",
        "windowLower": 0,
        "windowUpper": 0
      },
      {
        "id": "timing_31",
        "name": "Total Study Duration",
        "type": "Within",
        "unit": "weeks",
        "instanceType": "Timing",
        "value": 46,
        "relativeTo": "Study Start",
        "windowLower": 0,
        "windowUpper": 46
      },
      {
        "id": "timing_32",
        "name": "Total Study Duration with SARS-CoV-2",
        "type": "Within",
        "unit": "weeks",
        "instanceType": "Timing",
        "value": 48,
        "relativeTo": "Study Start",
        "windowLower": 0,
        "windowUpper": 48
      },
      {
        "id": "timing_33",
        "name": "F4cc Total Study Duration",
        "type": "Within",
        "unit": "weeks",
        "instanceType": "Timing",
        "value": 60,
        "relativeTo": "Study Start",
        "windowLower": 0,
        "windowUpper": 60
      },
      {
        "id": "timing_34",
        "name": "Chest X-ray Validity Window",
        "type": "Within",
        "unit": "weeks",
        "instanceType": "Timing",
        "value": 12,
        "relativeTo": "Screening",
        "windowLower": -12,
        "windowUpper": 0
      },
      {
        "id": "timing_35",
        "name": "IGRA Validity Window",
        "type": "Within",
        "unit": "weeks",
        "instanceType": "Timing",
        "value": 12,
        "relativeTo": "Screening",
        "windowLower": -12,
        "windowUpper": 0
      }
    ],
    "conditions": [
      {
        "id": "cond_1",
        "name": "Pro-C3 Eligibility Threshold",
        "instanceType": "Condition",
        "description": "Fibrogenic activity marker threshold for eligibility",
        "text": "Pro-C3 ≥12.6 ng/mL at Week -8 (SV1)"
      },
      {
        "id": "cond_2",
        "name": "ELF Score Eligibility Threshold",
        "instanceType": "Condition",
        "description": "Enhanced Liver Fibrosis score threshold for eligibility",
        "text": "ELF score ≥7.7 at Week -8 (SV1)"
      },
      {
        "id": "cond_3",
        "name": "NASH Histological Criteria",
        "instanceType": "Condition",
        "description": "Biopsy-confirmed NASH criteria",
        "text": "NAS ≥3 with at least 1 point in lobular inflammation"
      },
      {
        "id": "cond_4",
        "name": "Fibrosis Stage Eligibility",
        "instanceType": "Condition",
        "description": "Acceptable fibrosis stages for enrollment",
        "text": "Liver fibrosis stage F1 through F4cc according to NASH CRN"
      },
      {
        "id": "cond_5",
        "name": "F4cc Fibrosis Criteria",
        "instanceType": "Condition",
        "description": "Non-invasive criteria for F4 compensated cirrhosis",
        "text": "FIB-4 ≥3.48 and LSM ≥20 kPa or Agile 4 score ≥0.57"
      },
      {
        "id": "cond_6",
        "name": "AST Exclusion Threshold",
        "instanceType": "Condition",
        "description": "AST level exclusion criterion",
        "text": "AST levels >5×ULN"
      },
      {
        "id": "cond_7",
        "name": "ALT Exclusion Threshold",
        "instanceType": "Condition",
        "description": "ALT level exclusion criterion",
        "text": "ALT levels >5×ULN"
      },
      {
        "id": "cond_8",
        "name": "ALP Exclusion Threshold",
        "instanceType": "Condition",
        "description": "Alkaline phosphatase exclusion criterion",
        "text": "ALP ≥2×ULN"
      },
      {
        "id": "cond_9",
        "name": "Serum Creatinine Exclusion",
        "instanceType": "Condition",
        "description": "Renal function exclusion criterion",
        "text": "Serum creatinine ≥1.5×ULN or eGFR <45 mL/min/1.73 m2"
      },
      {
        "id": "cond_10",
        "name": "INR Exclusion Threshold",
        "instanceType": "Condition",
        "description": "Coagulation exclusion criterion",
        "text": "INR ≥1.3 (except for participants receiving anticoagulant treatment)"
      },
      {
        "id": "cond_11",
        "name": "Total Bilirubin Exclusion",
        "instanceType": "Condition",
        "description": "Bilirubin exclusion criterion",
        "text": "TBL ≥ULN (except for Gilbert's syndrome with normal direct bilirubin)"
      },
      {
        "id": "cond_12",
        "name": "Direct Bilirubin Exclusion",
        "instanceType": "Condition",
        "description": "Direct bilirubin exclusion criterion",
        "text": "Direct bilirubin ≥3×ULN"
      },
      {
        "id": "cond_13",
        "name": "Platelet Count Exclusion",
        "instanceType": "Condition",
        "description": "Platelet count exclusion criterion",
        "text": "Platelet count <60×10^9/L"
      },
      {
        "id": "cond_14",
        "name": "Decompensated Liver Disease",
        "instanceType": "Condition",
        "description": "Liver decompensation exclusion criteria",
        "text": "Presence or history of ascites, hepatic encephalopathy, or variceal bleeding"
      },
      {
        "id": "cond_15",
        "name": "Child-Pugh Score Exclusion",
        "instanceType": "Condition",
        "description": "Child-Pugh classification exclusion",
        "text": "Child-Pugh >6 (Class B or C), unless due to therapeutic anticoagulation"
      },
      {
        "id": "cond_16",
        "name": "MELD Score Exclusion",
        "instanceType": "Condition",
        "description": "MELD score exclusion criterion",
        "text": "MELD score >12"
      },
      {
        "id": "cond_17",
        "name": "F4cc Safety Clearance",
        "instanceType": "Condition",
        "description": "Safety requirement before F4cc enrollment",
        "text": "Safety and tolerability established in first four noncirrhotic (F1-F3) participants who have received at least 3 doses of ontamalimab 75 mg and have been monitored for at least 12 weeks after the first dose"
      },
      {
        "id": "cond_18",
        "name": "F1 Enrollment Cap",
        "instanceType": "Condition",
        "description": "Maximum F1 fibrosis participants",
        "text": "Not more than four participants with F1 fibrosis will be enrolled"
      },
      {
        "id": "cond_19",
        "name": "Age Eligibility",
        "instanceType": "Condition",
        "description": "Age range for participation",
        "text": "Aged 18 to 70 years, inclusive"
      },
      {
        "id": "cond_20",
        "name": "Clinically Concerning Liver Chemistry",
        "instanceType": "Condition",
        "description": "Investigator discretion for elevated liver enzymes",
        "text": "AST or ALT >4×ULN may be clinically concerning and requires investigator consultation with sponsor"
      },
      {
        "id": "cond_21",
        "name": "Positive IGRA Management",
        "instanceType": "Condition",
        "description": "Criteria for managing indeterminate IGRA results",
        "text": "If both initial and confirmatory IGRA results are indeterminate, participant may be enrolled after negative Mantoux tuberculin skin test and consultation with specialist determining low risk of infection"
      }
    ],
    "conditionAssignments": [],
    "transitionRules": [
      {
        "id": "trans_1",
        "name": "Screening to Liver Biopsy Transition",
        "instanceType": "TransitionRule",
        "transitionType": "Epoch Transition",
        "fromElementId": "epoch_screening_sv1",
        "toElementId": "epoch_screening_sv2",
        "text": "Participants with Pro-C3 ≥12.6 ng/mL and ELF score ≥7.7 who meet inclusion criteria and none of exclusion criteria at SV1 will be eligible for liver biopsy at SV2"
      },
      {
        "id": "trans_2",
        "name": "Screening to Treatment Transition",
        "instanceType": "TransitionRule",
        "transitionType": "Epoch Transition",
        "fromElementId": "epoch_screening",
        "toElementId": "epoch_treatment",
        "text": "Indication for NASH (NAS ≥3 with at least 1 point in lobular inflammation) and liver fibrosis stage F1 through F4cc in the liver biopsy will enable participants to enroll in the study"
      },
      {
        "id": "trans_3",
        "name": "F4cc Enrollment Gate",
        "instanceType": "TransitionRule",
        "transitionType": "Epoch Transition",
        "fromElementId": "epoch_screening_f4cc",
        "toElementId": "epoch_treatment",
        "text": "After safety and tolerability have been established in the first four noncirrhotic (F1-F3) participants who have received at least 3 doses of ontamalimab 75 mg and have been monitored for at least 12 weeks after the first dose, eligible F4cc participants will be allowed to enroll"
      },
      {
        "id": "trans_4",
        "name": "Treatment to Follow-up Transition",
        "instanceType": "TransitionRule",
        "transitionType": "Epoch Transition",
        "fromElementId": "epoch_treatment",
        "toElementId": "epoch_followup",
        "text": "All participants, including those who discontinue, will undergo a safety follow-up period through 12 weeks after the last dose of study drug"
      },
      {
        "id": "trans_5",
        "name": "Discontinuation for AST Elevation",
        "instanceType": "TransitionRule",
        "transitionType": "Discontinuation",
        "fromElementId": "epoch_treatment",
        "toElementId": "epoch_followup",
        "text": "AST levels >5×ULN requires discontinuation"
      },
      {
        "id": "trans_6",
        "name": "Discontinuation for ALT Elevation",
        "instanceType": "TransitionRule",
        "transitionType": "Discontinuation",
        "fromElementId": "epoch_treatment",
        "toElementId": "epoch_followup",
        "text": "ALT levels >5×ULN requires discontinuation"
      },
      {
        "id": "trans_7",
        "name": "Liver Chemistry Stopping Rule",
        "instanceType": "TransitionRule",
        "transitionType": "Discontinuation",
        "fromElementId": "epoch_treatment",
        "toElementId": "epoch_followup",
        "text": "Liver chemistry stopping criteria per algorithm for study drug discontinuation"
      },
      {
        "id": "trans_8",
        "name": "PML Symptom Discontinuation",
        "instanceType": "TransitionRule",
        "transitionType": "Discontinuation",
        "fromElementId": "epoch_treatment",
        "toElementId": "epoch_followup",
        "text": "Any unexplained symptoms suggestive of progressive multifocal leukoencephalopathy (PML) based on targeted neurological assessment"
      },
      {
        "id": "trans_9",
        "name": "SARS-CoV-2 Screening Pause",
        "instanceType": "TransitionRule",
        "transitionType": "Epoch Transition",
        "fromElementId": "epoch_screening",
        "toElementId": "epoch_screening_extended",
        "text": "In case of positive test for SARS-CoV-2 infection, screening may be paused for an additional 2 weeks"
      },
      {
        "id": "trans_10",
        "name": "Screen Failure to Rescreen",
        "instanceType": "TransitionRule",
        "transitionType": "Epoch Transition",
        "fromElementId": "screen_failure",
        "toElementId": "epoch_screening",
        "text": "An individual who has been designated a screen failure may be rescreened once"
      },
      {
        "id": "trans_11",
        "name": "Decompensation Discontinuation",
        "instanceType": "TransitionRule",
        "transitionType": "Discontinuation",
        "fromElementId": "epoch_treatment",
        "toElementId": "epoch_followup",
        "text": "New signs of decompensation and/or clinically meaningful change in disease status including presence of ascites, hepatic encephalopathy, or variceal bleeding"
      }
    ],
    "scheduleTimelineExits": [
      {
        "id": "exit_1",
        "name": "Study Completion",
        "exitType": "Completion",
        "instanceType": "ScheduleTimelineExit",
        "description": "Completion of all protocol-required visits through Week 36 (end of follow-up period)"
      },
      {
        "id": "exit_2",
        "name": "Early Termination - Participant Request",
        "exitType": "Early Termination",
        "instanceType": "ScheduleTimelineExit",
        "description": "Participant may discontinue for any reason"
      },
      {
        "id": "exit_3",
        "name": "Early Termination - Safety",
        "exitType": "Early Termination",
        "instanceType": "ScheduleTimelineExit",
        "description": "Discontinuation due to adverse events or safety concerns including liver chemistry stopping criteria"
      },
      {
        "id": "exit_4",
        "name": "Early Termination - PML Suspicion",
        "exitType": "Early Termination",
        "instanceType": "ScheduleTimelineExit",
        "description": "Discontinuation due to unexplained symptoms suggestive of progressive multifocal leukoencephalopathy"
      },
      {
        "id": "exit_5",
        "name": "Screen Failure",
        "exitType": "Early Termination",
        "instanceType": "ScheduleTimelineExit",
        "description": "Participant does not meet eligibility criteria during screening period"
      },
      {
        "id": "exit_6",
        "name": "Lost to Follow-up",
        "exitType": "Early Termination",
        "instanceType": "ScheduleTimelineExit",
        "description": "Participant unavailable for follow-up assessment"
      },
      {
        "id": "exit_7",
        "name": "Protocol Deviation Exit",
        "exitType": "Early Termination",
        "instanceType": "ScheduleTimelineExit",
        "description": "Investigator concern for participant's compliance with protocol procedures"
      },
      {
        "id": "exit_8",
        "name": "Decompensation Exit",
        "exitType": "Early Termination",
        "instanceType": "ScheduleTimelineExit",
        "description": "Development of decompensated liver disease during study participation"
      }
    ],
    "scheduledDecisionInstances": [
      {
        "id": "dec_1",
        "name": "Liver Biopsy Eligibility Decision",
        "timepointId": "sv1_week_minus_8",
        "instanceType": "ScheduledDecisionInstance",
        "description": "Decision point at SV1 to determine eligibility for liver biopsy at SV2 based on Pro-C3 and ELF thresholds",
        "conditionIds": [
          "cond_1",
          "cond_2"
        ]
      },
      {
        "id": "dec_2",
        "name": "Enrollment Eligibility Decision",
        "timepointId": "sv2_week_minus_6",
        "instanceType": "ScheduledDecisionInstance",
        "description": "Decision point after liver biopsy to determine enrollment eligibility based on NASH histology and fibrosis stage",
        "conditionIds": [
          "cond_3",
          "cond_4"
        ]
      },
      {
        "id": "dec_3",
        "name": "F4cc Enrollment Gate Decision",
        "timepointId": "f4cc_safety_review",
        "instanceType": "ScheduledDecisionInstance",
        "description": "Decision point to allow F4cc participant enrollment after safety established in first four F1-F3 participants",
        "conditionIds": [
          "cond_17"
        ]
      },
      {
        "id": "dec_4",
        "name": "Week 12 Safety Assessment",
        "timepointId": "week_12",
        "instanceType": "ScheduledDecisionInstance",
        "description": "Safety assessment including FibroScan and liver chemistry evaluation",
        "conditionIds": [
          "cond_6",
          "cond_7"
        ]
      },
      {
        "id": "dec_5",
        "name": "Week 24 Treatment Completion Assessment",
        "timepointId": "week_24",
        "instanceType": "ScheduledDecisionInstance",
        "description": "End of treatment assessment including liver biopsy, cT1 MRI, FibroScan, and HepQuant-SHUNT DSI",
        "conditionIds": [
          "cond_3",
          "cond_4"
        ]
      },
      {
        "id": "dec_6",
        "name": "Liver Chemistry Stopping Decision",
        "timepointId": "any_treatment_visit",
        "instanceType": "ScheduledDecisionInstance",
        "description": "Ongoing decision point for liver chemistry stopping criteria evaluation per algorithm",
        "conditionIds": [
          "cond_6",
          "cond_7",
          "cond_20"
        ]
      },
      {
        "id": "dec_7",
        "name": "IGRA Result Management Decision",
        "timepointId": "screening",
        "instanceType": "ScheduledDecisionInstance",
        "description": "Decision point for managing indeterminate IGRA results with potential specialist consultation",
        "conditionIds": [
          "cond_21"
        ]
      }
    ],
    "summary": {
      "timingCount": 35,
      "conditionCount": 21,
      "transitionRuleCount": 11,
      "exitCount": 8
    }
  }
}